Insulin pumps and continuous glucose monitoring (CGM) are commonly used by patients with diabetes mellitus in the outpatient setting. The efficacy and safety of initiating inpatient insulin pumps and CGM in the nonintensive care unit setting is unknown.
Materials and Methods:
In a prospective pilot study, inpatients with type 2 diabetes were randomized to receive standard subcutaneous basal-bolus insulin and blinded CGM (group 1, n = 5), insulin pump and blinded CGM (group 2, n = 6), or insulin pump and nonblinded CGM (group 3, n = 5). Feasibility, glycemic control, and patient satisfaction were evaluated among groups.
Results:
Group 1 had lower mean capillary glucose levels, 144.5 ± 19.5 mg/dL, compared with groups 2 and 3, 191.5 ± 52.3 and 182.7 ± 59.9 mg/dL (P1 vs. 2+3 = 0.05). CGM detected 19 hypoglycemic episodes (glucose <70 mg/dL) among all treatment groups, compared with 12 episodes detected by capillary testing, although not statistically significant. No significant differences were found for the total daily dose of insulin or percentage of time spent below target glucose range (<90 mg/dL), in target glucose range (90–180 mg/dL), or above target glucose range (>180 mg/dL). On the Diabetes Treatment Satisfaction Questionnaire-Change, group 3 reported increased hyperglycemia and decreased hypoglycemia frequency compared with the other two groups, although the differences did not reach statistical significance.
Conclusions:
Insulin pump and CGM initiation are feasible during hospitalization, although they are labor intensive. Although insulin pump initiation may not lead to improved glycemic control, there is a trend toward CGM detecting a greater number of hypoglycemic episodes. Larger studies are needed to determine whether use of this technology can lower inpatient morbidity and mortality.
Get full access to this article
View all access options for this article.
References
1.
CookCB, CastroJC, SchmidtRE, et al.: Diabetes care in hospitalized noncritically ill patients: more evidence for clinical inertia and negative therapeutic momentum. J Hosp Med, 2007; 2:203–211.
2.
WexlerDJ, MeigsJB, CaglieroE, et al.: Prevalence of hyper- and hypoglycemia among inpatients with diabetes: a national survey of 44 U.S. hospitals. Diabetes Care, 2007; 30:367–369.
3.
BraithwaiteSS, BuieMM, ThompsonCL, et al.: Hospital hypoglycemia: not only treatment but also prevention. Endocr Pract, 2004; 10(Suppl 2):89–99.
4.
QuealeWS, SeidlerAJ, BrancatiFL: Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. Arch Intern Med, 1997; 157:545–552.
5.
ClementS, BraithwaiteSS, MageeMF, et al.: Management of diabetes and hyperglycemia in hospitals. Diabetes Care, 2004; 27:553–591.
6.
MendezCE, MokKT, AtaA, et al.: Increased glycemic variability is independently associated with length of stay and mortality in noncritically ill hospitalized patients. Diabetes Care, 2013; 36:4091–4097.
7.
GoldenSH, Peart-VigilanceC, KaoWH, et al.: Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care, 1999; 22:1408–1414.
8.
FrischA, ChandraP, SmileyD, et al.: Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care, 2010; 33:1783–1788.
9.
BrunoA, LevineSR, FrankelMR, et al.: Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology, 2002; 59:669–674.
10.
ZuurbierSM, HiltunenS, TatlisumakT, et al.: Admission hyperglycemia and clinical outcome in cerebral venous thrombosis. Stroke, 2016; 47:390–396.
11.
CapesSE, HuntD, MalmbergK, et al.: Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet, 2000; 355:773–778.
12.
McAlisterFA, MajumdarSR, BlitzS, et al.: The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care, 2005; 28:810–815.
13.
SchuetzP, FriedliN, GrolimundE, et al.: Effect of hyperglycaemia on inflammatory and stress responses and clinical outcome of pneumonia in non-critical-care inpatients: results from an observational cohort study. Diabetologia, 2014; 57:275–284.
14.
YoungB, OttL, DempseyR, et al.: Relationship between admission hyperglycemia and neurologic outcome of severely brain-injured patients. Ann Surg, 1989; 210:466–472.
15.
ScaleaTM, BochicchioGV, BochicchioKM, et al.: Tight glycemic control in critically injured trauma patients. Ann Surg, 2007; 246:605–610.
16.
StahnA, PistroschF, GanzX, et al.: Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diabetes Care, 2014; 37:516–520.
17.
RubinDJ, GoldenSH: Hypoglycemia in non-critically ill, hospitalized patients with diabetes: evaluation, prevention, and management. Hosp Pract, 2013; 41:109–116.
18.
MoghissiES, KorytkowskiMT, DiNardoM, et al.: American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract, 2009; 15:353–369.
19.
UmpierrezGE, SchwartzS: Use of incretin-based therapy in hospitalized patients with hyperglycemia. Endocr Pract, 2014; 20:933–944.
20.
BellidoV, SuarezL, RodriguezMG, et al.: Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes. Diabetes Care, 2015; 38:2211–2216.
21.
CookCB, BoyleME, CisarNS, et al.: Use of continuous subcutaneous insulin infusion (insulin pump) therapy in the hospital setting: proposed guidelines and outcome measures. Diabetes Educ, 2005; 31:849–857.
22.
LeonhardiBJ, BoyleME, BeerKA, et al.: Use of continuous subcutaneous insulin infusion (insulin pump) therapy in the hospital: a review of one institution's experience. J Diabetes Sci Technol, 2008; 2:948–962.
23.
NassarAA, PartlowBJ, BoyleME, et al.: Outpatient-to-inpatient transition of insulin pump therapy: successes and continuing challenges. J Diabetes Sci Technol, 2010; 4:863–872.
24.
FauldsER, WyneKL, BuschurEO, et al.: Insulin pump malfunction during hospitalization: two case reports. Diabetes Technol Ther, 2016; 18:399–403.
25.
BodurHA, SaygiliF, SaygiliS, et al.: Continuous infusion of subcutaneous compared to intravenous insulin for tight glycaemic control in medical intensive care unit patients. Anaesth Intensive Care, 2008; 36:520–527.
26.
LeeIT, LiauYJ, LeeWJ, et al.: Continuous subcutaneous insulin infusion providing better glycemic control and quality of life in type 2 diabetic subjects hospitalized for marked hyperglycemia. J Eval Clin Pract, 2010; 16:202–205.
27.
BurtMG, RobertsGW, Aguilar-LozaNR, et al.: Brief report: comparison of continuous glucose monitoring and finger-prick blood glucose levels in hospitalized patients administered basal-bolus insulin. Diabetes Technol Ther, 2013; 15:241–245.
28.
GomezAM, UmpierrezGE, MunozOM, et al.: Continuous glucose monitoring versus capillary point-of-care testing for inpatient glycemic control in type 2 diabetes patients hospitalized in the general ward and treated with a basal bolus insulin regimen. J Diabetes Sci Technol, 2015; 10:325–329.
29.
SchauppL, DonsaK, NeubauerKM, et al.: Taking a closer look—continuous glucose monitoring in non-critically ill hospitalized patients with type 2 diabetes mellitus under basal-bolus insulin therapy. Diabetes Technol Ther, 2015; 17:611–618.
LevittDL, SilverKD, SpanakisEK: Mitigating severe hypoglycemia by initiating inpatient continuous glucose monitoring for type 1 diabetes mellitus. J Diabetes Sci Technol, 2017; 11:440–441.
32.
BodeBW, SabbahHT, GrossTM, et al.: Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev, 2002; 18:S14–S20.
33.
BertheE, LireuxB, CoffinC, et al.: Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. Horm Metab Res, 2007; 39:224–229.
34.
GargSK, SchwartzS, EdelmanSV: Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care, 2004; 27:734–738.
35.
FDA: Instructions for use Dexcom STS sensor. 2006. 2016. www.accessdata.fda.gov/cdrh_docs/pdf5/P050012C.pdf (accessed August14, 2016).
36.
GarberAJ, MoghissiES, BransomeEDJr., et al.: American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract, 2004; 10:S4–S9.
37.
BradleyC, PlowrightR, StewartJ, et al.: The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. Health Qual Life Outcomes, 2007; 5:57.
38.
BradleyC: Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care, 1999; 22:530–532.
39.
DunganKM, SagrillaC, Abdel-RasoulM, et al.: Prandial insulin dosing using the carbohydrate counting technique in hospitalized patients with type 2 diabetes. Diabetes Care, 2013; 36:3476–3482.
40.
ThurberKM, DierkhisingRA, ReilandSA, et al.: Mealtime insulin dosing by carbohydrate counting in hospitalized cardiology patients: a retrospective cohort study. Diabetes Technol Ther, 2016; 18:15–21.
41.
KlonoffDC, BuckinghamB, ChristiansenJS, et al.: Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2011; 96:2968–2979.
42.
WalliaA, UmpierrezGE, NasrawaySA, et al.: Round table discussion on inpatient use of continuous glucose monitoring at the International Hospital Diabetes Meeting. J Diabetes Sci Technol, 2016; 10:1174–1181.
43.
VigerskyRA, FondaSJ, ChellappaM, et al.: Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care, 2012; 35:32–38.
44.
AhnD, PettusJ, EdelmanS: Unblinded CGM should replace blinded CGM in the clinical management of diabetes. J Diabetes Sci Technol, 2016; 10:793–798.
CurkendallSM, NatoliJL, AlexanderCM, et al.: Economic and clinical impact of inpatient diabetic hypoglycemia. Endocr Pract, 2009; 15:302–312.
47.
CookCB, BeerKA, SeifertKM, et al.: Transitioning insulin pump therapy from the outpatient to the inpatient setting: a review of 6 years' experience with 253 cases. J Diabetes Sci Technol, 2012; 6:995–1002.
48.
JayasekaraRS, MunnZ, LockwoodC: Effect of educational components and strategies associated with insulin pump therapy: a systematic review. Int J Evid Based Healthc, 2011; 9:346–361.
49.
FDA: CGM summary of safety and effectiveness data. 2014. 2016. www.accessdata.fda.gov/cdrh_docs/pdf12/P120005S018b.pdf (accessed June18, 2016).
50.
MaahsDM, DeSalvoD, PyleL, et al.: Effect of acetaminophen on CGM glucose in an outpatient setting. Diabetes Care, 2015; 38:e158–e159.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
